LONDON, UK / ACCESSWIRE / April 30, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has entered into an exclusive 12-month option agreement with Silk Road Therapeutics Inc, for a nominal fee, to acquire a novel topical muco-adherent formulation of Pentoxifylline (tPTX) for the treatment of oral ulcers in patient's suffering from Behçet's Disease.
BAUDETTE, Minn., Jan. 23, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pentoxifylline Extended-Release (ER) Tablets, USP...
Neuraxpharm to increase branded business through upcoming acquisition of established products from Sanofi
The objective of this study was to evaluate the compatibility of 10 commonly used active pharmaceutical ingredients (APIs) compounded in oral suspensions using a globally available suspending vehicle (SyrSpend SF PH4 liquid): caffeine 10.0?mg/mL, carvedilol 1.0?mg/mL, clomipramine hydrochloride 5.0?mg/mL, folic acid 1.0?mg/mL, hydrochlorothiazide 5.0?mg/mL, loperamide hydrochloride 1.0?mg/mL, methotrexate 2.5?mg/mL, nadolol 10.0?mg/mL, naltrexone hydrochloride 1.0?mg/mL and pentoxifylline 20.0?mg/mL, stored at both controlled refrigerated (2–8°C) and room (20–25°C) temperature.
Anvisa Suspends the Import of All Pharmaceutical Raw Materials from Sinbiotik SA, Mexico
Heartburn Drugs Have Serious Side Effects